MedTrace Logo

New Biomarkers in Parkinson's Disease

NCT05150158 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-12-08

No results posted yet for this study

Summary

Parkinson's disease (PD) is the second most common neurodegenerative disease and its prevalence is expected to double over the next 30 years, making it a leading cause of neurological disability \[GBD 2016 Neurology Collaborators, 2019; Dorsey et al, 2018\]. PD is characterized by motor symptoms, such as muscle stiffness, tremor, slowness of movement (bradykinesia) and postural instability, and non-motor symptoms, such as sphincter disorders, postural hypotension, cognitive disorders, depression, hyposmia, constipation and REM sleep behavioral disturbance. Unfortunately, the mechanisms leading to neuronal dysfunction and death in PD remain poorly known and there are currently no therapies capable of modifying their course \[Bloem et al, 2021\].

In this study we aim at defining a new set of biomarkers based on the combination between PET, blood metabolomics and natural language extracted from the keywords of electronic health records.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • NIM Competence Center for Digital Healthcare GmbH

    collaborator UNKNOWN

  • Neuromed IRCCS

    lead OTHER

Principal Investigators

  • Nicola D'Ascenzo · Istituto Neurologico Mediterraneo NEUROMED I.R.C.C.S

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05150158 on ClinicalTrials.gov